NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»27/08/2009 [Industry news]
China includes AOBO products in Essential Drug List

Chinese pharma company American Oriental Bioengineering (AOBO) announced that 61 of its products have been included in Chinas Essential Drug List (EDL). AOBO currently manufactures and markets six of the sixty one products,

 
Chinese pharma company American Oriental Bioengineering (AOBO) announced that 61 of its products have been included in Chinas Essential Drug List (EDL). AOBO currently manufactures and markets six of the sixty one products, including one of its leading products, Jinji Yimucao. Additionally, the company is actively exploring marketing other AOBO products included in the EDL. China Ministry of Health (MoH) released the EDL on August 18, 2009. After a rigorous selection process, an expert evaluation group selected three hundred and seven \"essential medicines\" from tens of thousands of products. Inclusion in the EDL ensures that products deemed to be essential medicines are available to the public at appropriate dosages and at affordable rates, at all times. Inclusion in the EDL also ensures inclusion in the National Medical Insurance Catalog, which reimburses manufacturers. Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering said, \"We believe we are well-positioned in the context of China\'s healthcare reform, and we are aligned with the China overall efforts to enhance medical care and coverage nationally. The announcement speaks to our commitment to efficacy and high quality. Our status as a designated branded supplier will boost distributor confidence and retail sales efforts. Going forward, AOBO will continue to be aligned with China healthcare efforts as we maintain our vision and dedication to improving consumer health in China.\"

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.